Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00170768 · ClinicalTrials.gov registry record · Phase 2
Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over
A Phase 2 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT00170768 is a Phase 2 study that has completed, run by Novartis. The registered enrollment target is 150 participants.
The verdict
NCT00170768, a Phase 2 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
The purpose of this study is to explore the possible cognitive effects of darifenacin modified release and long-acting oxybutynin.
Interventions
- DRUG Placebo
- DRUG Oxybutynin
- DRUG Darifenacin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2005-02 |
| Est. Completion | 2005-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00170768
The ClinicalTrials.gov registry entry for NCT00170768 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00170768 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00170768 about?
NCT00170768 is a clinical study titled "Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over". The purpose of this study is to explore the possible cognitive effects of darifenacin modified release and long-acting oxybutynin.
What is the current status of trial NCT00170768?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2005-02. Estimated completion is 2005-05.
What interventions are being tested in trial NCT00170768?
The interventions under investigation include: Placebo (DRUG), Oxybutynin (DRUG), Darifenacin (DRUG).
Who is sponsoring clinical trial NCT00170768?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.